Loading
An immune checkpoint on exhausted T cells and on leukaemic stem cells; antibodies against it failed in lung cancer and MDS after strong preclinical promise. This dossier gathers the 2 products (0 approved), 2 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Type I transmembrane receptor of the TIM family; ligand binding recruits BAT3 release and inhibits TCR signalling; on myeloid cells it regulates innate responses. Marks terminal exhaustion together with PD-1, LAG-3 and TIGIT.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Metastatic cancer | immune% | Immune-cell target (TIM-3 checkpoint on exhausted T cells and myeloid cells): expressed on immune cells rather than on the tumour, so patient selection rests on the cancer type and, in trials, on PD-L1 or immune biomarkers. |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 1/2 | Active | A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. | - | ||
| 1/2 | Recruiting | A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"TIM-3" OR ABSTRACT:"TIM-3" OR TITLE:"HAVCR2" OR ABSTRACT:"HAVCR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TIM-3, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/tim3.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/tim3.json. Licence CC BY-NC 4.0.